NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 124 filers reported holding NGM BIOPHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $154,000 | -99.6% | 12 | -99.5% | 0.00% | -100.0% |
| Q1 2022 | $34,905,000 | -6.4% | 2,289 | +8.7% | 0.01% | +11.1% |
| Q4 2021 | $37,278,000 | +1806.8% | 2,105 | +2163.4% | 0.01% | – |
| Q3 2021 | $1,955,000 | -92.5% | 93 | -92.2% | 0.00% | -100.0% |
| Q2 2021 | $25,945,000 | -86.4% | 1,188 | -81.8% | 0.01% | -88.9% |
| Q1 2021 | $190,080,000 | +7.8% | 6,539 | +12.4% | 0.05% | +3.8% |
| Q4 2020 | $176,278,000 | – | 5,819 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 15,396,116 | $303,611,000 | 42.97% |
| Ponoi II Management, LLC | 1,298,908 | $25,614,000 | 20.76% |
| Ponoi Management, LLC | 1,298,908 | $25,614,000 | 14.23% |
| Euclidean Capital LLC | 1,493,349 | $29,449,000 | 9.56% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $74,279,000 | 6.80% |
| Aquilo Capital Management, LLC | 1,194,237 | $23,550,000 | 6.12% |
| Greenspring Associates, LLC | 1,573,357 | $31,027,000 | 2.10% |
| Octagon Capital Advisors LP | 200,000 | $3,944,000 | 0.82% |
| Redmile Group, LLC | 2,792,448 | $55,067,000 | 0.82% |
| BVF INC/IL | 955,000 | $18,833,000 | 0.71% |